Retina Implant said today that it won CE Mark approval in the European Union for the latest iteration of its subretinal implant for patients blinded by retinitis pigmentosa.
The Alpha AMS is the next-generation version of the Alpha IMS, which won CE Mark approval back in July 2013. The Reutlingen, Germany-based company said the new device increases the number of pixels from 1,500 to 1,600, claiming the title for most electrodes of any neuroprosthetic implant.
“We are delighted by the news that our latest device has received the CE Mark. We believe that being able to provide physicians access to the Alpha AMS represents a notable step forward in treatment options for their patients,” CEO Walter-G Wrobel said in prepared remarks. “We look forward to making our technology commercially available to the patient community across Europe. We would also like to thank those patients who participated in the clinical trials to date – they have been critical to the success of our research and evolution of the Alpha AMS.”
Earlier this month, Retina Implant drummed up a $28 million round it plans to use to fund new clinical centers and win reimbursement in more markets for the Alpha IMS.